InsidersTradesSigma
Spectrum Pharmaceuticals INC: directors' dealings · United States · SEC (Form 4)
SEC:spectrum-pharmaceuticals-incUS·SEC (Form 4)Healthcare & Pharma
Explore the full management transaction log of Spectrum Pharmaceuticals INC, a publicly traded company based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Spectrum Pharmaceuticals INC has published 31 reports. The latest transaction was reported on 23 June 2022 — Attribution. Among the most active insiders: LEBEL FRANCOIS. The full history is accessible without an account.
31
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€172,767
19 ops.
Sell Volume
Financial data
Last declaration on 23 June 2022
Declarations31 total
Executives◆Grant19SEC
0334,507 shares0
Common Stock, $0.001 par value
SEC:0001209191-22-039057:0·
Executives◆Grant11SEC
0405,040 shares0
Common Stock, $0.001 par value
SEC:0001209191-22-039063:0·
Executives◆Grant22SEC
0405,040 shares0
Common Stock, $0.001 par value
SEC:0001209191-22-039065:0·
Executives◆Grant11SEC
0246,085 shares0
Common Stock, $0.001 par value
SEC:0001209191-22-039066:0·
Executives▼Sale34SEC
€4,2565,711 shares@ €0.7453100.0% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-038810:0·
Executives▼Sale25SEC
€3,1924,283 shares@ €0.7453100.0% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-038809:0·
Executives▼Sale34SEC
€3,1924,283 shares@ €0.7453100.0% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-038806:0·
Executives▼Sale29SEC
€1,4821,205 shares@ €1.232.5% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-023224:0·
Executives◆Grant11SEC
04,759 shares0
Common Stock, $0.001 par value
SEC:0001209191-22-021178:0·
Executives▼Sale34SEC
€13,30520,653 shares@ €0.644251.5% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-019297:0·
Executives▼Sale32SEC
€9,44314,658 shares@ €0.644228.3% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-019316:0·
Executives▼Sale43SEC
€13,11420,356 shares@ €0.644230.6% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-019304:0·
Executives▼Sale32SEC
€16,19025,130 shares@ €0.644227.0% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-019341:0·
Executives▼Sale34SEC
€12,54420,215 shares@ €0.620548.5% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-012804:0·
Executives▼Sale30SEC
€8,35613,466 shares@ €0.620513.9% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-012928:0·
Executives▼Sale32SEC
€8,38513,513 shares@ €0.620525.1% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-012838:0·
Executives▼Sale43SEC
€12,38119,953 shares@ €0.620528.9% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-012912:0·
Executives◆Grant19SEC
€6,02610,000 shares@ €0.6026100.0% of flow
Common Stock, $0.001 par value
SEC:0001209191-22-009266:0·
Executives▼Sale13SEC
€14,0217,363 shares@ €1.904323.4% of flow
Common Stock, $0.001 par value
SEC:0001209191-21-064002:0·
Executives▼Sale26SEC
€19,9265,821 shares@ €3.42333.2% of flow
Common Stock, $0.001 par value
SEC:0001209191-21-042775:0·
Executives◆Grant11SEC
014,277 shares0
Common Stock, $0.001 par value
SEC:0001209191-21-042486:0·
Executives◆Grant11SEC
014,277 shares0
Common Stock, $0.001 par value
SEC:0001209191-21-042434:0·
Executives◆Grant11SEC
014,277 shares0
Common Stock, $0.001 par value
SEC:0001209191-21-042419:0·
Executives◆Grant11SEC
014,277 shares0
Common Stock, $0.001 par value
SEC:0001209191-21-042453:0·
Executives◆Grant11SEC
014,277 shares0
Common Stock, $0.001 par value
SEC:0001209191-21-042495:0·
25 of 31 declarations
About Spectrum Pharmaceuticals INC
Geographically, Spectrum has operated primarily from the United States and serves the U.S. market, with exposure to the country’s healthcare system, payers, and hospital distribution channels. SEC filings also show reliance on third-party manufacturers for certain inputs, active pharmaceutical ingredients, and logistics services, which is important when assessing operational resilience. In short, Spectrum Pharmaceuticals Inc. remains a U.S. biopharmaceutical stock listed on the NASDAQ, with a specialized and higher-risk profile, whose recent history has been defined by portfolio contraction, strategic refocusing, and greater dependence on a limited set of clinical and commercial catalysts.
